MedTrace Logo

Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

NCT00113295 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-04-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the safety and efficacy of quetiapine for generalized anxiety disorder patients who remain symptomatic despite treatment with paroxetine CR.

Conditions

  • Anxiety Disorder

Interventions

DRUG

Continued Paroxetine CR

DRUG

Quetiapine

DRUG

Placebo

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Naomi M Simon, MD · Massachusetts General Hospital

  • Kathryn Connors, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2007-02-28
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00113295 on ClinicalTrials.gov